-Shinsaku Nakagawa Researcher Activity Profile

Research Author Detailed Information 

Shinsaku Nakagawa Publication Rate By Year

Shinsaku Nakagawa has published 1 paper(s) in 2006, 9 paper(s) in 2007, 7 paper(s) in 2008, for a total of 17 research publications in total.

Shinsaku S Nakagawa Author Information

LAST NAME: nakagawa

FIRST NAME: shinsaku

INITIALS: S

AFFILIATION:

Papers

Shinsaku Nakagawa's Publication Record

1. [Biological characteristics of an established model of ovarian cancer in mice and its homologous cell lines] Year Published: 2006
Department of Gynecology and Obstetrics/Research Center, The Fourth Affiliated Hospital, Hebei Medical University, Shijiazhuang, Hebei, 050011, P. R. China.
2. [Gene expression of tumor cells both in vitro and in vivo enhanced by integrin-targeting adenovirus vector] Year Published: 2007
Institute of Pharmaceutics, Zhejiang University, Hangzhou 310031, China. gaojianqing1029@yahoo.com.cn
3. TERT promoter-driven adenovirus vector for cancer gene therapy via systemic injection. Year Published: 2007
Department of Biotechnology and Therapeutics, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6, Yamadaoka, Suita, Osaka 565-0871, Japan.
4. Efficient generation of antigen-specific cellular immunity by vaccination with poly(gamma-glutamic acid) nanoparticles entrapping endoplasmic reticulum-targeted peptides. Year Published: 2007
Department of Biotechnology and Therapeutics, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan.
5. CC-chemokine ligand 17 gene therapy induces tumor regression through augmentation of tumor-infiltrating immune cells in a murine model of preexisting CT26 colon carcinoma. Year Published: 2007
Department of Biotechnology and Therapeutics, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka, Japan.
6. Improved cytosolic translocation and tumor-killing activity of Tat-shepherdin conjugates mediated by co-treatment with Tat-fused endosome-disruptive HA2 peptide. Year Published: 2007
Laboratory of Pharmaceutical Proteomics, National Institute of Biomedical Innovation, 7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan.
7. Optimization of protein therapies by polymer-conjugation as an effective DDS. Year Published: 2007
Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan.
8. Improved cytosolic translocation and tumor-killing activity of Tat-shepherdin conjugates mediated by co-treatment with Tat-fused endosome-disruptive HA2 peptide. Year Published: 2007
Laboratory of Pharmaceutical Proteomics, National Institute of Biomedical Innovation, 7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan.
9. Efficient generation of antigen-specific cellular immunity by vaccination with poly(gamma-glutamic acid) nanoparticles entrapping endoplasmic reticulum-targeted peptides. Year Published: 2007
Department of Biotechnology and Therapeutics, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan.
10. Development of amphiphilic gamma-PGA-nanoparticle based tumor vaccine: potential of the nanoparticulate cytosolic protein delivery carrier. Year Published: 2008
Department of Biotechnology and Therapeutics, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan.
11. Creation and X-ray structure analysis of the tumor necrosis factor receptor-1-selective mutant of a tumor necrosis factor-alpha antagonist. Year Published: 2008
National Institute of Biomedical Innovation, 7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan.
12. Optimization of protein therapies by polymer-conjugation as an effective DDS. Year Published: 2007
Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan.
13. Development of amphiphilic gamma-PGA-nanoparticle based tumor vaccine: potential of the nanoparticulate cytosolic protein delivery carrier. Year Published: 2008
Department of Biotechnology and Therapeutics, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan.
14. Preparation of a tat-related transporter Peptide for carrying the adenovirus vector into cells. Year Published: 2008
Life Science Center, Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Minatojima, Chuo-ku, Kobe 650-8586, Japan. kawasaki@pharm.kobegakuin.ac.jp.
15. Innate immune response induced by gene delivery vectors. Year Published: 2008
Laboratory of Gene Transfer and Regulation, National Institute of Biomedical Innovation, Osaka, Japan; Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.
16. Development of PEGylated adenovirus vector with targeting ligand. Year Published: 2008
Department of Biotechnology and Therapeutics, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan.
17. Modification of pIX or hexon based on fiberless Ad vectors is not effective for targeted Ad vectors. Year Published: 2008
Laboratory of Gene Transfer and Regulation, National Institute of Biomedical Innovation, Osaka 567-0085, Japan.